4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pneumonia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 787 ongoing clinical trials involving Pneumonia
Of the 787 trials,198 trials are in Phase III
Furthermore, 195 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Pneumonia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pneumonia, an Infectious Disease condition. The largest number of ongoing clinical trials for Pneumonia is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Pneumonia-related drug trials.

Pfizer Inc: The leading ongoing Pneumonia related clinical trial sponsor

Pfizer Inc is the top sponsor for Pneumonia-related ongoing clinical trials.

Tongji Hospital, University Hospital of Lille, London School of Hygiene & Tropical Medicine and China National Biotech Group Co Ltd are among other notable clinical trial sponsors involved in Pneumonia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pneumonia

Pneumococcal 13-valent conjugate vaccine, Tacrolimus (Modigraf, Prograf, Prograft) and Pneumococcal polysaccharide vaccine are among the key marketed drugs involving Pneumonia.

Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) [Prevnar 13/Prevenar 13] is a sterile suspension of polysaccharides of the capsular antigens of Streptococcus pneumoniae. Pneumococcal 13-valent conjugate vaccine is formulated as injection intended for intramuscular administration. Pneumococcal 13-valent conjugate vaccine was first approved in 2009 and is marketed globally in the US, UK, China, Japan, Germany, and France by Pfizer Inc and its subsidiaries.

Tacrolimus (Modigraf, Prograf, Prograft) is an immunosuppressive agent. It functions via Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor mechanism of action. Tacrolimus is formulated as hard gelatin capsules, granules, powder for suspension for oral route of administration and injectable solution for intravenous and intravascular route of administration. Tacrolimus was first approved in 1993 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Astellas Pharma US Inc.